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Received August 25, 2013; accepted December 24, 2013AbstractSurgery is the main treatment for curing gastric cancer. Early diagnosis provides an excellent survival outcome via an improved detection of
early gastric cancer and an improved resection rate. The extent of lymphadenectomy surgery has been under debate for a long time. In East Asian
countries, especially Japan, Korea, and Taiwan, gastrectomy with D2 dissection is routinely performed. By contrast, in most Western countries,
gastrectomy with D1 dissection is performed, due to lower mortality and morbidity. Recently, acceptance of D2 surgery has increased in Western
countries because: (1) modified D2 lymphadenectomy (preservation of pancreas and spleen) improves operative morbidity and mortality; (2)
Western surgeons can be trained to performed D2 lymph node dissection on Western patients safely; and (3) D2 resection decreases locoregional
recurrence and prolongs survival. Current guidelines in the United States and Europe suggest modified D2 dissection is recommended, but needs
to be performed by high-volume centers with experienced surgeons. Adjuvant or perioperative chemotherapy should be prescribed for gastric
cancer with Stage II or III disease, due to its marked benefits of reducing disease recurrence and increasing long-term survival. Patients with
inoperable advanced gastric cancer should receive chemotherapy to improve their survival and quality of life if an acceptable performance status
can be achieved. Targeted therapy with trastuzumab should be considered in patients with HER-2/neu overexpression who have a higher
response rate and a longer survival.
Copyright  2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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31. Introduction
Gastric cancer remains a major health problem around the
world, despite declined incidence in recent decades.1,2 It is the
fourth most common cancer worldwide, with about one million
(988,000) new cases annually and the second leading cause of
cancer death (736,000 deaths per year) in 2008, according to theConflicts of interest: The authors declare that there are no conflicts of interest
related to the subject matter or materials discussed in this article.
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1726-4901/Copyright  2014 Elsevier Taiwan LLC and the Chinese Medical AssWorld Health Organization GLOBOCAN database. The inci-
dence is geographically related. Rates are highest in Eastern
Asia (such as in Korea, Japan, and China), Eastern Europe, and
South America, and the lowest rates are in North America.
Surgery is the only curative modality to treat gastric cancer.
However, the cancer has a high recurrence rate after operation,
especially in advanced stages. Adjuvant therapy with chemo-
therapy, chemoradiotherapy, or perioperative chemotherapy can
provide survival benefit. Two large randomized controlled trials
(RCTs) showed a lower recurrence rate and better survival after
prescription of adjuvant chemotherapy.4,5 Early diagnosis is
crucial to provide excellent survival benefit. The 5-year survival
rate by the seventh edition of American Joint Committee on
Cancer (AJCC) is 89.2e95.1% in Stage IA, 84.9e88.4% inociation. All rights reserved.
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43.8e58.4% in Stage IIIA, 31.1e46.8% in Stage IIIB, and
13.1e28.1% in Stage IIIC.6e8 In Japan and Korea, where
screening is widely performed, early detection is often
possible.9 In Japanese annual and nationwide registry data from
13,626 patients in 2002, the resection rate is high (95.4%) and
the incidence of early gastric cancer (pT1) from resection pa-
tients is 49.7%. The overall 5-year survival is 68.9%.8 By
contrast, inWestern countries, gastric cancer is often detected at
an advanced stage and prognosis remains poor. In this article, we
will review the treatment of gastric cancer, including resectable
and unresectable diseases.
2. Surgery
Surgical intervention is the only modality that is potentially
curative for gastric cancer. Standard gastrectomy is the prin-
cipal surgical procedure, involving resection of at least two-
thirds of the stomach, with lymph node dissection and
adequate margin (4 cm).10 Standard gastrectomy is
comprised of total gastrectomy and distal subtotal gastrectomy
for clinically node-positive or T2e4a tumors. Some patients
with clinical T1 and N0 can receive modified gastric resection
according to tumor location as follows: (1) pylorus-preserving
gastrectomy for tumors in the middle part of the stomach with
a distal tumor border at least 4 cm proximal to the pylorus; and
(2) proximal gastrectomy for proximal tumors where more
than half of the distal stomach can be preserved.11
Regional lymph node dissection is an important part of
radical gastrectomy, due to frequent node metastases in gastric
cancer.12 Pathologic examination and evaluation of lymph
node stations that surround the stomach have been suggested
by the Japanese Research Society for the Study of Gastric
Cancer since 1963.13 The perigastric lymph node stations are
grouped together as N1, including along the lesser curvature
(stations 1, 3, and 5) and greater curvature (stations 2, 4, andTable 1
Phase III randomized trials comparing D1 with D2/D3 lymphadenectomy.
Patient numbers
Cuschieri et al16 (The British
Cooperative trial), 1999
D1: n ¼ 200
D2: n ¼ 200
(1987e1994)
Dutch Gastric Cancer Group Trial:
(1) Hartgrink et al,19 2004
(2) Songun et al20 (15-year
follow-up), 2010
D1: n ¼ 380
D2: n ¼ 331
(1989e1993)
Lower local regional recurrence (13
(37 vs. 48) in D2 lymphadenectom
Sasako et al24 (Japan Clinical Oncology
Group Study 9501, JCO), 2008
D2: n ¼ 263
D2 þ paraaortic node dissection:
n ¼ 260 (1995e2001)
Wu et al25,26 (Taiwan, single-institution
randomized trial), 2004, 2006
D1: n ¼ 110
D3: n ¼ 111a (1993e1999)
Degiuli et al28 (Italian Gastric Cancer
Study Group, IGCSG), 2010
D1: n ¼ 133
D2 with modification:b
n ¼ 134 (1998e2005)
Data are presented as %.
a D3 lymphadenectomy by 1st edition of Japanese classification of Gastric Carc
b D2 with modification: spleen preservation in most patients.6) of the stomach. The nodes along the celiac artery and its
branches are grouped together as N2, including the left gastric
artery (station 7), common hepatic artery (station 8), celiac
artery (station 9), and splenic artery (stations 10 and 11). More
distant nodes, including the paraaortic (N3 and N4), are
regarded as distant metastases. Minor modifications of the
grouping system are necessary according to the location of the
primary tumor [e.g., proximal lymph nodes at station 1 (right
paracardial lymph nodes) were classified into the N1 group in
upper third gastric cancer but classified into the N2 group in
the lower third tumor]. D1 gastrectomy is defined as dissection
of all the N1 group nodes, and D2 is defined as dissection of
all the N1 and N2 group nodes.14 In the new Japanese clas-
sification and treatment guidelines for gastric cancer published
by the Japanese Gastric Cancer Association in 2011, the
definition of lymphadenectomy has been simplified: the lymph
node stations to be dissected in D1 and D2 are prescribed by
the kind of gastrectomy, regardless of the tumor location. In
total gastrectomy, D1 is defined as N1þstation 7 (left gastric
artery) lymph node dissection, D2 is N1þN2 lymph node
dissection, and D0 is incomplete resection of N1 lymph
nodes.11,15
The extent of lymphadenectomy is debated and there is no
consensus in the world. In Japan, D2 dissection was intro-
duced in the 1960s and has been recommended as standard
practice with low morbidity and low mortality.12 However, in
most Western countries, gastrectomy with only D1 dissection
is performed, due to having a lower mortality and morbidity
than D2 dissection.16,17
Several large prospective, randomized trials investigated
the extent of lymph node dissection and survival
(Table 1).16,19,20,24e26,28 In Western countries, there were two
large randomized control trials (RCTs). The first one was
conducted by the Medical Research Council in the United
Kingdom, with 400 patients randomized to D1 or D2 lym-
phadenectomy.16,18 There was no significant difference of 5-Postoperative
morbidity
Postoperative
mortality
Overall survival
28 6.5 35
46 13 33
p < 0.001 p ¼ 0.04 p ¼ 0.43 (5-year survival)
25 4 30
43 10 35
p < 0.001 p ¼ 0.004 p ¼ 0.53
vs. 19) and lower gastric-cancer-related death rates
y
20.9
28.1
p ¼ 0.067
0.8
0.8
p ¼ 0.99
69.2
70.3
p ¼ 0.85 (5-year survival)
7.3
17.1
0
0
59.5, 53.6
p ¼ 0.041 (5-year survival)
12.0
17.9 (p ¼ 0.178)
3.0
2.2 (p ¼ 0.722)
No available data
inoma in 1995.
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hazard ratio (HR) ¼ 1.03, 95% confidence intervals (CI)
0.82e1.29] in the two groups. However, the morbidity (28%
vs. 46%) and mortality (6.5% vs. 13.5%) were higher in the
D2 group. The second trial was the Dutch Gastric Cancer
Trial (DGCT). A total of 711 patients were randomly assigned
to undergo either a D1 or D2 lymphadenectomy.19 The me-
dian follow-up was 11 years. The results demonstrated no
significant difference in overall survival (30% vs. 35%,
p ¼ 0.53). In a subgroup analysis, there was a trend to benefit
in the N2 disease group (positive lymph nodes between 7 and
15, AJCC Cancer Staging Manual 6th edition). In addition,
the morbidity (25% vs. 43%) and mortality (4% vs. 10%)
were also higher in the D2 group. After a median follow-up of
15 years, the D2 lymphadenectomy was associated with lower
locoregional recurrence and lower gastric-cancer-related death
rate than the D1 surgery.20
In Eastern Asian countries, such as Korea and Japan, where
the incidence of gastric adenocarcinoma is the highest in the
world, D2 lymphadenectomy is routinely performed by
experienced surgeons with low morbidity and mortality and
clinical trials. Comparing D1 to D2 would be considered un-
ethical today.21,22 Seoul National University Hospital, which
performed almost 1000 operations for gastric cancer per year,
reported a morbidity rate of 17.4% and mortality rate of
0.6%.23 In a prospective, randomized trial (JCOG 9501) from
Japan of D2 versus extended paraaortic lymphadenectomy, the
morbidity rate was 20.9e28.1%, and the mortality rate was
0.8%.24 Investigators in another Eastern Asian country,
Taiwan, conducted a prospective randomized trial, enrolling
221 patients who were randomly assigned to D1 surgery or D3
surgery.25 The three participating surgeons were well-trained
and had done at least 25 independent D3 dissections prior to
the start of the trial. Morbidity (10.1% vs. 17.1%) was higher
in the extended lymphadenectomy (D3) group, but there were
no deaths (mortality 0%) in either group. Overall 5-year sur-
vival was significantly higher in patients receiving D3 surgery
(59.5% vs. 53.6%, p ¼ 0.041).26 The recurrence rates at 5
years were lower in D3 surgery but without statistical signif-
icance (40.3% vs. 50.6%, p ¼ 0.197).26
In the Dutch Gastric Cancer trial, when hospital deaths
were excluded, D2 resection had a trend for survival benefit.
Survival rates were 32% for D1 (n ¼ 365) and 39% for D2
(n ¼ 299), and the relative risks of these patients favored the
D2 lymphadenectomy (p ¼ 0.07).19,22 More recent studies
have shown that Western surgeons can be trained to perform
D2 lymph node dissection on Western patients with low
morbidity and mortality. One retrospective trial in Spain
assessed 85 patients who underwent D1 lymphadenectomy
and 71 who received D2 lymphadenectomy in a single insti-
tution.27 The results showed a longer 5-year survival in the D2
group than in the D1 group (50.6% vs. 41.4%, p ¼ 0.03), with
low postoperative mortality (0% vs. 2.3% for D2 and D1,
respectively, p ¼ 0.295). Another prospective RCT was con-
ducted by the Italian Gastric Cancer Study Group (IGCSG) to
compare D1 and D2 gastrectomy in specialized Western
centers.28 A total of 267 patients with gastric cancer wererandomly assigned to either a D1 or a D2 resection in five
specialized centers. The results demonstrated no difference in
the postoperative mortality rates (D1: 3.0% vs. D2: 2.2%,
p ¼ 0.722) and overall morbidity rates (D1: 12.0% vs. D2:
17.9%, p ¼ 0.178). In a trial employing randomized adjuvant
chemoradiation study (Intergroup 0116), reanalysis of the
impact of hospital volume on the outcome of patients who
underwent D0 comparing with D1 or D2 lymphadenectomy
was performed.29 The results demonstrated there was a trend
toward improved overall survival among patients who received
a D1 or D2 lymphadenectomy at moderate- to high-volume
cancer centers.
Initially, distal pancreatectomy and splenectomy (pan-
creaticosplenectomy) were performed routinely to remove
lymph node metastases at the splenic artery (station 11) and
splenic hilum (station 10) in D2 gastrectomy for proximal
third gastric cancer.30,31 There was a marked adverse effect on
both mortality and morbidity of distal pancreatectomy and
splenectomy in two RCTs in Western countries18,32 and no
survival benefit of pancreaticosplenectomy compared with
splenectomy alone by two Japanese retrospective trials.33,34
Pancreas-preserving splenectomy has been considered an
effective and safe procedure without decreasing surgical
curability.35,36 Currently, distal pancreatectomy is considered
beneficial only when the primary tumor or metastatic lymph
node directly invades the pancreas, but is not performed for
prophylactic resection.21,22
Unlike the distal pancreatectomy, resection of the spleen
continues to be controversial. According to the Japanese
experience with lymph node dissection at the splenic hilus
with splenectomy, the incidence of hilar node metastasis
ranged from 15% to approximately 21% for tumors located at
or infiltrate to the proximal third of the stomach.31 About
20e25% of patients with lymph node metastasis have survived
over 5 years following lymphadenectomy with splenectomy.
Two prospective RCTs of total gastrectomy and lymphade-
nectomy, with or without splenectomy, have been performed
in Chile and South Korea.37,38 Both studies demonstrated a
marginally better 5-year survival rate in patients with sple-
nectomy, but the survival difference was not statistically sig-
nificant. A higher rate of infectious complications in the spleen
resection group from the Chile study was noted. However, the
numbers of patients in these two studies were 187 and 207,
respectively, and thus the power of these studies to confirm a
modest improvement in survival for splenectomy is limited. In
Japan, a large multicenter randomized trial (JCOG 0110,
recruiting 500 patients) to evaluate the role of splenectomy for
proximal gastric cancer is currently ongoing.39 In Japan, in
patients with potentially curable T2eT4 tumors invading the
greater curvature of the upper stomach, complete clearance of
No. 10 nodes by splenectomy should be considered by Japa-
nese treatment guidelines.11
In conclusion, the D2 dissection has been the standard
procedure in eastern Asia for a long time and also recom-
mended in Western countries in recent years. In the treatment
guidelines of gastric cancer in the United States and Europe,
gastrectomy with modified D2 dissection is recommended, but
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surgical expertise and postoperative care.40,41
3. Endoscopic therapy
Endoscopic resection for gastric cancer is considered as
curative when there is an extremely low possibility of lymph
node metastasis and it is suitable for en bloc resection.11 The
endoscopic resection comprises endoscopic mucosal resection
(EMR) and endoscopic submucosal dissection (ESD). The
absolute indications for EMR and ESD include a
differentiated-type adenocarcinoma without ulcerative find-
ings, depth of invasion in the mucosa (clinically diagnosed as
T1a), and diameter <2 cm. ESD has a higher rate of en bloc
resection and a better cumulative recurrence-free rate (97.6%
vs. 92.5%, p ¼ 0.01) than EMR.42 In two large retrospective
studies, 3843 and 5265 patients with early gastric cancer
received D2 gastrectomy, respectively.12,43 Tumors of the
following categories have a very low possibility for lymph
node metastasis (0%)12,43 and are regarded as expanded in-
dications: tumors clinically diagnosed as invasion in the mu-
cosa (cT1a) and: (1) of differentiated-type without ulcer
formation and irrespective of tumor size; (2) differentiated-
type with ulcer formation and tumor size 3 cm; or (3)
undifferentiated-type without ulcer formation and tumor size
2 cm. Under the expanded indications, ESD but not EMR
should be employed for en bloc resection and may provide
potential curative treatment. One large retrospective trial in
Korea with 1152 patients who received ESD for early gastric
cancer showed no statistically significant difference of recur-
rence rates in the absolute indication and in the expanded
indication groups (7.7% vs. 9.3%, p ¼ 0.524).44 The long-term
follow-up and survival data remain insufficient for ESD under
the expanded criteria, and the procedure should be performed
with caution.11 A prospective clinical trial to evaluate the ef-
ficacy and safety of ESD under the expanded indications by
the Japan Clinical Oncology Group (JCOG0607) is ongoing.45
4. Laparoscopic resection
Laparoscopic surgery has been increasingly employed,
largely for early gastric cancer (T1 tumor) which is unsuitable
for EMR. A recent meta-analysis study of laparoscopy-assisted
versus open distal gastrectomy for early gastric cancer,
including 22 trials and 3411 patients, demonstrated that: (1) the
long-term outcome of cancer recurrence rate or survival was
similar between both groups; (2) the numbers of retrieved lymph
nodes were close in the two groups; and (3) there was signifi-
cantly less postoperative morbidity (such as blood loss, post-
operative analgesic consumption, and hospital stay) in the
laparoscopic surgery group.46 In gastric cancer more advanced
than early cancer, there is less solid evidence regarding safety
and long-term outcome. One small prospective randomized
study of laparoscopic versus open subtotal gastrectomy for
distal gastric cancer fromHuscher and colleagues47 showed: (1)
no significant difference in operative mortality, with 3.3% for
the laparoscopic surgery versus 6.7% for open surgery andmorbidity of 26.7% versus 27.6%, respectively; (2) the number
of resected lymph nodes was also not significantly different; and
(3) 5-year overall survival (58.9% vs. 55.7%) and 5-year
disease-free survival (57.3% vs. 54.8%) were similar between
laparoscopic surgery and open surgery groups. However, lapa-
roscopic surgery is technically demanding, and solid evidence
regarding safety and long-term outcome remains lacking. It
should be considered as an investigational treatment and re-
quires further investigation in randomized clinical trials.
5. Radiation5.1. Neoadjuvant chemoradiation therapyThe role of preoperative chemoradiation treatment for pa-
tients with resectable gastric cancer still remains uncertain. In
resectable adenocarcinoma of the lower esophagus, esoph-
agogastric junction, or gastric cardia, preoperative chemo-
radiation provides survival benefit, from two small-scale
randomized studies.48,49 The multicenter German PreOperative
chemotherapy or radiochemotherapy in Esophagogastric
adenocarcinoma Trial (POET) study included 119 patients with
locally advanced adenocarcinoma of the lower esophagus or
esophagogastric junction.48 Patients who received preoperative
chemoradiotherapy followed by surgery had a significantly
higher pathologic complete response (15.6% vs. 2.0%) or
tumor-free lymph nodes (64 vs. 38%). The 3-year survival rate
showed improvement (47% vs. 28%). Although the study was
ended prematurely due to low accrual, and statistical signifi-
cance was not achieved, there was a trend towards survival
advantage. Another randomized study demonstrated that pre-
operative chemoradiation was superior to surgery alone in pa-
tients with resectable adenocarcinoma of the esophagus (74
patients) and gastric cardia (39 patients).49 The results showed:
(1) a lower rate of lymph node metastasis (42% vs. 82%,
p< 0.001); and (2) improved overall survival (16 months vs. 11
months, p ¼ 0.01) in the preoperative chemoradiation group.
However, there have been no randomized studies to survey
the benefits of preoperative chemoradiotherapy in noncardiac
gastric cancer. Only several Phase II trials were done, which
showed that preoperative chemoradiation provided pathologic
complete response rates which ranged from 20% to 30%, and
70% to 78% achieved complete (R0) resection.50e52 Neo-
adjuvant chemoradiotherapy for patients with resectable
gastric cancer remains unclear. An international prospective
Phase III randomized trial is still ongoing.535.2. Adjuvant chemoradiation therapyAdjuvant chemoradiation therapy has become the standard
in America, since the landmark Intergroup randomized trial
SWOG 9008/INT-0116 demonstrated the survival benefit of
the therapy when compared with surgery alone.54 The study
showed that five monthly cycles of chemotherapy (5-
fluorouracil and leucovorin) with concurrent radiotherapy
(45 Gy) during cycles 2 and 3 resulted in an approximately
22% improvement in 3-year overall survival. However, only
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dissection, and 54% had a D0 lymphadenectomy. There was
no survival difference in patients who received D2 resection.
In Europe, postoperative chemoradiation has not gained wide
acceptance due to concerns about (late) toxicity with abdom-
inal chemoradiation, and the quality of surgery used.41 In
Japan, where standardized D2 lymph node dissection provides
good local tumor control, postoperative chemoradiation is
usually not performed.11 A recent randomized Phase III trial in
Korea (ARTIST trial, n ¼ 458) which compared adjuvant
chemoradiation (capecitabine and cisplatin plus radiotherapy)
with adjuvant chemotherapy after curative D2 lymph node
dissection of gastric cancer showed that adjuvant chemo-
radiation did not improve disease-free survival.55
6. Chemotherapy6.1. Adjuvant chemotherapyTwo large Asian randomized Phase III studies (the ACTS
GC and CLASSIC trials) have confirmed the survival benefit
for postoperative chemotherapy after curative D2 lymph node
dissection in patients with gastric cancer.4,5 Postoperative
chemotherapy with oral S-1 (ACTS GC trial) or capecitabine
plus oxaliplatin (CLASSIC trial) were prescribed in patients
with Stage II or Stage III after D2 lymph node dissection. In
the CLASSIC study, the 3-year disease-free survival was 74%
in the chemotherapy and surgery group and 59% in the surgery
only group (HR 0.56, 95% CI 0.44e0.72). The 3-year sur-
vivals were 83% and 78%, respectively in the surgery withTable 2
Phase III randomized trials of chemotherapy in patients with gastric cancer.
Regimen (patient’s number)
Al-Batran,60 (in Germany) 2008 FLP (n ¼ 108)
FLO (n ¼ 112)
Van Cutsem et al62 (V325 trial), 2006 DCF (n ¼ 221)
CF (n ¼ 224)
Cunningham et al63 (REAL-2 trial), 2008 ECF (n ¼ 249)
ECX (n ¼ 241)
EOF (n ¼ 235)
EOX (n ¼ 239)
Kang et al58 (ML 17032), 2009 XP (n ¼ 139)
FP (n ¼ 137)
Bang et al61 (TOGA trial), 2010 XP or FP (n ¼ 290)
T þ XP or FP (n ¼ 294)
Ajani et al59 (FLAGS trial), 2010 5-FU þ cisplatin (n ¼ 526)
S-1 þ cisplatin (n ¼ 527)
Ohtsu et al74 (AVAGAST trial), 2011 XP or FP (n ¼ 387)
bevacizumab þ XP or FP (n ¼ 387)
DCF ¼ docetaxel þ cisplatin þ 5-fluorourcail (5-FU); ECF ¼ epirubicin
EOF ¼ epirubicin þ oxaliplatin þ 5-FU; FLO ¼ 5-FU þ leucovorin þ oxa
PFS ¼ progression-free survival; T ¼ trastuzumab; TTP ¼ time to progression; Xchemotherapy group and surgery alone group (HR 0.72, 95%
CI 0.52e1.00).4 In the ACTS-GC study, the 5-year disease-
free survival was 65.4% in the S1 group and 53.1% in the
surgery only group (HR 0.653, 95% CI 0.537e0.793). The 5-
year survivals were 71.7% and 61.1% (HR 0.669, 95% CI
0.540e0.828), respectively, in the surgery with chemotherapy
group and surgery-alone group.556.2. Perioperative chemotherapyThe first well-powered Phase III trial (MAGIC trial) for
perioperative chemotherapy was conducted by the British
Medical Research Council.56 In this trial, 503 patients with
adenocarcinoma of the stomach (74%), lower esophagus
(15%), or esophagogastric junction (11%) were randomized to
receive either perioperative chemotherapy (ECF: epirubicin,
cisplatin, and fluorouracil) followed by surgery or surgery
alone. The 5-year survival rates were 36% among those who
received perioperative chemotherapy and 23% in the surgery
group. The results of this study showed that perioperative
chemotherapy with the ECF regimen significantly improved
progression-free and overall survival in patients with resect-
able gastroesophageal adenocarcinomas.6.3. Chemotherapy for advanced metastatic diseaseChemotherapy can provide improved survival and delay the
appearance of disease-related symptoms compared to the best
supportive care in patients with unresectable gastric can-
cer.12e14 Although chemotherapy regimens have achievedResponse rate, % Median PFS/TTP (mo) Median overall
survival (mo)
24.5
34.8
3.9
5.8
p ¼ 0.077
8.8
10.7
p ¼ 0.506
37
25
p ¼ 0.01
5.6
3.7
p < 0.001
9.2
8.6
p ¼ 0.02
40.7
46.4
42.7
47.9
6.2
6.7
6.5
7.0
9.9
9.9
9.3
11.2
41
29
p ¼ 0.020
5.6
5.0
p < 0.001 (noninferiority)
p ¼ 0.080 (superiority)
10.5
9.3
p ¼ 0.008 (noninferiority)
p ¼ 0.265 (superiority)
35
47
p ¼ 0.0017
5.5
6.7
p ¼ 0.0002
13.8
11.1
p ¼ 0.0046
29.1
31.9
p ¼ 0.40
5.5
4.8
p ¼ 0.92
8.6
7.9
p ¼ 0.20
37.4
46
p ¼ 0.0315
5.3
6.7
p ¼ 0.0037
10.1
12.1
p ¼ 0.0301
þ cisplatin þ 5-FU; ECX ¼ epirubicin þ cisplatin þ capecitabine;
liplatin; FLP ¼ 5-FU þ leucovorin þ cisplatin; FP ¼ 5-FU þ cisplatin;
P ¼ capecitabine þ cisplatin.
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cure. The median survival time remains 8.6e11.1 months in
large clinical trials (Table 2).57e64,74
A meta-analysis of randomized gastric cancer trials has
revealed that combination chemotherapy results in substan-
tially improved overall survival compared with single-agent
chemotherapy.65 There is no single well-established standard
regimen in current use, but fluoropyrimidine- and platinum-
based combinations are the most widely used in the world.
It remains controversial whether a triplet regimen is needed.
The meta-analysis showed significant benefits from adding an
anthracycline to a platinum and fluoropyrimidine doublet, and
ECF (epirubicin plus cisplatin plus protracted infusion 5-
fluorouracil) is among the most active and well-tolerated
regimens.65 The combination of docetaxel, cisplatin, and 5-
fluorouracil (DCF) was evaluated in a randomized Phase III
study (V325 trial).62 The median overall survival was signif-
icantly longer for DCF compared with CF (9.2 months vs. 8.6
months; p ¼ 0.02). However, DCF was associated with
increased myelosuppression and infectious complications.
Twenty-nine percent developed neutropenia. Modification of
the regimen can obtain similar activity and is better
tolerated.66
Oxaliplatin is the third generation of platinum and is as
effective as cisplatin. One Phase III trial conducted by a
German Study Group in 2008, randomly assigned patients to
receive combination treatment of fluorouracil, leucovorin, and
oxaliplatin (FLO) or fluorouracil, leucovorin, and cisplatin
(FLP). The results demonstrated no statistically significant
difference in median overall survival (10.7 months vs. 8.8
months) between the FLO and FLP groups.60 Another Phase
III trial (REAL-2) compared capecitabine with fluorouracil
and oxaliplatin with cisplatin in 1003 patients with advanced
esophagogastric cancer.63 Results from this study showed
oxaliplatin was as effective as cisplatin and associated with
lower incidences of Grade 3 or Grade 4 neutropenia, alopecia,
renal toxicity, and thromboembolism, but with slightly higher
incidences of Grade 3 or Grade 4 diarrhea and neuropathy.
Capecitabine is an oral fluoropyrimidine which is converted
to 5-fluorouracil intracellularly. Two Phase III trials (REAL-2
and ML 17032) demonstrated that capecitabine was not infe-
rior to fluorouracil in terms of progression-free and overall
survival.58,63
Another novel oral fluoropyrimidine, S-1, has shown
promise in advanced gastric cancer. In the Phase III random-
ized trial [First Line Advanced Gastric Cancer Study,
(FLAGS) trial], 1053 patients with advanced gastric or
esophagogastric junction adenocarcinoma were randomized to
either cisplatin plus S-1 or cisplatin plus 5-fluorouracil.59 The
results showed no difference in median overall survival (8.6
months and 7.9 months, respectively; p ¼ 0.20), but cisplatin
and S-1 were associated with a significantly improved safety
profile. In a randomized Phase III trial (SPIRITS trial), 298
patients with advanced gastric cancer were randomly assigned
to S-1 plus cisplatin or S-1 alone.67 Median overall survival
(13.0 months vs. 11.0 months, p ¼ 0.04) and progression-free
survival (6.0 months vs. 4.0 months, p < 0.0001) weresignificantly longer in patients with a combination of S-1 and
cisplatin compared with S-1 alone. In Japan, the first-line
regimen of chemotherapy for advanced gastric cancer is S-1
plus cisplatin.15
Irinotecan is a topoisomerase I inhibitor widely used for
colorectal cancer. In several Phase II studies, irinotecan
showed activity in advanced gastric cancer, with response rates
ranging from 15% to 23%.68e70 The results of a Phase III
study in 2008, randomly comparing irinotecan plus 5-
fluorouracil and folinic acid (IF) to cisplatin combined with
5-fluorouracil (CF), demonstrated slightly superior results in
the IF group, with response rates 31.8% versus 25.8%, time to
tumor progression (TTP) 5.0 months versus 4.2 months, and
overall survival 9.0 months versus 8.7 months, but no signif-
icant superiority or noninferiority was found.57 Irinotecan was
less toxic (improved tolerance) and showed a marginally sig-
nificant noninferiority in terms of TTP (HR 1.23, 95% CI
0.97e1.57 for a margin of noninferiority of 0.93), thus it can
be an alternative when platinum-based therapy cannot be
delivered.
7. Targeted therapy
Some selective targeted agents have been developed in
recent years. The only one showing strong evidence for
improved survival is trastuzumab. The ToGA trial was a Phase
III, multicenter, randomized study. A total of 594 patients with
gastric and esophagogastric junction adenocarcinoma with
HER2 overexpression were included.61 Of these, 298 received
trastuzumab plus chemotherapy (5-fluorouracil or capecitabine
and cisplatin) and 296 received chemotherapy alone. There
was a significant improvement in overall survival (13.8 months
vs. 11.1 months, p ¼ 0.0046) and progression-free survival
(6.7 months vs. 5.5 months, p ¼ 0.0002) when adding tras-
tuzumab to chemotherapy. Subgroup analysis demonstrated
that, in patients with immunohistochemistry (IHC) 2þ and fish
fluorescence in situ hybridization (FISH)-positive tumors or
IHC 3þ, there was a marked improvement in overall survival
(16.0 months vs. 11.8 months, HR 0.65, 95% CI 0.51e0.83)
when trastuzumab was combined with chemotherapy. The
toxicity was similar in both study arms. There was also no
difference in symptomatic congestive heart failure between
both arms. The study established the addition of trastuzumab
to chemotherapy as a new standard treatment for patients with
HER2-neu overexpression advanced gastric or esoph-
agogastric junction adenocarcinoma.
Bevacizumab is a monoclonal antibody against vascular
endothelial growth factor A. Clinical trials have shown that
bevacizumab, in combination with chemotherapy, has efficacy
against several malignancies, including colon cancer, breast
cancer, and lung cancer.71e73 In a recent Phase III study
(AVAGAST trial), 774 patients were randomly assigned to the
bevacizumab combination in chemotherapy (cisplatin plus 5-
fluorouracil or capecitabine) or chemotherapy alone.74
Although the primary end point, overall survival, was not
reached (12.1 months vs. 10.1 months; p ¼ 0.1002), adding
bevacizumab significantly increased progression-free survival
351C.-Y. Kuo et al. / Journal of the Chinese Medical Association 77 (2014) 345e353and overall response rate in the first-line treatment of advanced
gastric cancer. In the subgroup analysis, in patients recruited in
the United States, a benefit for overall survival was found,
although the improvement was not significant for patients
treated in Europe or in Asia.
In conclusion, gastrectomy with modified D2 dissection is
the acceptable standard treatment worldwide now, but needs to
be performed in high-volume centers by experienced surgeons.
Adjuvant or perioperative chemotherapy can lower the recur-
rence rate and provide survival benefit. In patients with
unresectable gastric cancer, chemotherapy and target therapy
should be considered to improve survival and delay the
appearance of disease-related symptoms.References
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